Zoloft

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zoloft

Zoloft is the trade name for the prescription-only synthetic medication containing the active ingredient Sertraline Hydrochloride. This compound is classified as a potent antidepressant and belongs to the group of Selective Serotonin Reuptake Inhibitors (SSRIs).

Property Description
Active ingredient Sertraline Hydrochloride
Form Oral Tablet, Film-coated Tablet, Oral Solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Neurotransmitter modulation; mood stabilization
Origin Synthetic compound

Defining Zoloft: Its Pharmaceutical Identity and Classification

Zoloft (Sertraline Hydrochloride) is a synthetic, prescription-only psychotherapeutic agent that requires medical authorization for use. The medication, originally manufactured by Pfizer, is a monotherapy preparation containing a single active ingredient. Its distinct positioning as a recognized second-generation antidepressant is supported by extensive pharmacological studies, and the classification as an SSRI differentiates it from older classes of psychoactive drugs by emphasizing its highly selective action.

Sertraline's Composition and Typical Dosage Forms

The active ingredient is Sertraline, provided as the hydrochloride salt to enhance stability and ensure proper bioavailability following oral administration. Zoloft is notable for offering an oral solution or concentrate, which distinguishes it from some alternatives that are available only in solid tablet form. This availability of both solid and liquid forms provides consumption options for adults and select pediatric patients. The general application of this compound is clinically recognized for helping patients maintain emotional stability during periods of elevated stress or anxiety.

The General Purpose of Serotonin Reuptake Inhibition

The primary objective of Sertraline is to help establish a more stable emotional and behavioral state by modulating a specific chemical in the brain known as serotonin. Its core action is the selective inhibition of serotonin reuptake by the neurons. By blocking this reabsorption process, the drug increases the functional availability of serotonin in the brain's signaling pathways, a mechanism intended to support the regulation of mood and feelings of general well-being. The primary mechanism of Sertraline is the potent and selective inhibition of neuronal serotonin reuptake.

Regulatory References

  1. EMA Zoloft Referral Page

What side effects are possible with Zoloft?

Possible Side Effects and Safety Information

The safety profile for Zoloft (Sertraline) is formally documented by government regulatory bodies, classifying adverse reactions by frequency and the physiological systems affected. Gastrointestinal and Nervous System Disorders account for many of the most frequently reported effects.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on clinical trial data, where the following are cited as being Very Common (occurring in ge 1 in 10 patients) in regulatory documents: insomnia, dizziness, headache, nausea, diarrhea, dry mouth, fatigue, and ejaculation failure in males. Common reactions (occurring in ge 1 in 100 patients) include decreased appetite, tremor, anxiety, and decreased libido.


Serious Adverse Reactions and Safety Constraints

The regulatory labeling explicitly documents the potential for rare but serious adverse reactions. These include the risk of Serotonin Syndrome, a potentially life-threatening condition. The label also contains statements regarding an increased risk of suicidal thoughts and behaviors in pediatric and young adult patients (age 24 and younger) during the initial months of treatment or following dose changes. Other documented serious effects include the potential for hyponatremia (low sodium levels), seizures, and angle-closure glaucoma.

Population-Specific Safety Notes

The medication is contraindicated for co-use with Monoamine Oxidase Inhibitors (MAOIs). Specific safety cautions are established for certain groups, including patients with hepatic impairment, where clearance of the drug is reduced. Use during the third trimester of pregnancy is associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation symptoms. Furthermore, abruptly stopping treatment may result in a discontinuation syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Sertraline overdose details specific clinical and physiological manifestations that warrant aggressive medical treatment. The official descriptions of overdose presentations primarily affect the central nervous system and cardiovascular systems. Manifestations documented in regulatory sources include somnolence, agitation, tremor, dizziness, and tachycardia, often accompanied by nausea and vomiting.

Documented High-Risk Outcomes

Regulatory agencies note the risk of Serotonin Syndrome, a severe condition that can manifest with intense neuro-muscular excitation. Life-threatening cardiovascular complications, specifically QTc prolongation and Torsade de Pointes, have been reported following overdose. Deaths have also been associated with Sertraline overdose, particularly when ingested with other drugs or alcohol.

Emergency Action Mandate

Immediate medical attention must be sought for all suspected overdose cases. Regulatory instruction explicitly requires contacting emergency services if the individual collapses, has a seizure, has trouble breathing, or cannot be awakened. Overdose management should be medically treated aggressively.

There is no specific antidote known for Sertraline. Treatment is based on mandated symptomatic and supportive care, including establishing and maintaining a patent airway, and continuous cardiac (ECG) and vital sign monitoring. Procedures such as forced diuresis or dialysis are officially stated as unlikely to be of benefit.

Therapeutic Uses of Zoloft

Sertraline (Zoloft) is commonly used across domains where additional symptomatic support is needed for conditions marked by increased discomfort or tension. It is considered relevant for use in conditions such as Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder (PTSD), and Social Anxiety Disorder.

The medication is applied when groups of symptoms, such as pervasive low mood, social avoidance, and the urgency of compulsive acts, create noticeable functional strain. It assists with maintaining functional stability by reducing the intensity and frequency of fear-based manifestations and supports general well-being during symptomatic phases.

“The support provided may help ease the overall symptom burden and assists with maintaining functional stability.”

Quick Fact: Supportive Management for Intrusive Thoughts and Phobic Avoidance Sertraline is considered relevant for easing symptoms related to persistent, unwanted cognitions and fear-based behavioral patterns that interfere with daily functioning.

This supportive role contributes to improved comfort by easing the overall symptom load, which may help patients cope more steadily with difficult emotional episodes.

Regulatory References

  1. NIH MedlinePlus overview of Sertraline

Eligibility and Restrictions for Use

Who Can and Cannot Use Zoloft?

This section details the population eligibility rules for Zoloft (Sertraline Hydrochloride) as documented in official governmental regulatory sources.


Eligibility and Absolute Contraindications

Classification Population/Condition Restriction Basis
Allowed Use Adults for all approved indications. Established efficacy and safety profile.
Contraindicated Patients taking Monoamine Oxidase Inhibitors (MAOIs), including Linezolid. Risk of Serotonin Syndrome.
Contraindicated Patients taking Pimozide. Risk of serious cardiac issues (QTc prolongation).
Contraindicated Patients with known Hypersensitivity to Sertraline. Risk of severe allergic reaction.

Age- and Condition-Based Restrictions

  • Pediatric Use: Use is established for children aged 6 years and older for Obsessive-Compulsive Disorder (OCD) only. Safety and effectiveness are not established for children under 6 or for non-OCD indications in adolescents.
  • Organ Function: Use is not recommended in patients with Moderate to Severe Hepatic Impairment; mild impairment requires a mandated dose reduction. No dosage adjustment is necessary for patients with renal impairment.
  • Pregnancy and Lactation: Use is conditional; third-trimester use is associated with neonatal risks, and use during lactation requires balancing benefit against potential infant exposure.
  • Monitoring Requirement: Patients aged 24 and younger require close monitoring for the emergence of suicidal thoughts and behaviors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sertraline Hydrochloride establishes mandatory restrictions and necessary monitoring for specific co-administered substances.

Strictly contraindicated combinations include all Monoamine Oxidase Inhibitors (MAOIs), such as Linezolid and Methylene Blue, due to the high risk of severe Serotonin Syndrome. A mandatory washout period is required: at least 14 days must elapse when transitioning from an MAOI to Sertraline, and 7 days when transitioning in the opposite direction. The co-administration of Pimozide is also contraindicated, as Sertraline inhibits its metabolism, leading to increased plasma levels and risk of QTc prolongation. The Oral Solution formulation is contraindicated with Disulfiram due to its alcohol content.

Pharmacodynamic interactions require caution with other serotonergic agents (e.g., Triptans, Tramadol) to mitigate the risk of Serotonin Syndrome. A separate pharmacodynamic interaction increases the documented risk of bleeding when Sertraline is used with Anticoagulants or Antiplatelet Agents (e.g., NSAIDs).

From a pharmacokinetic perspective, Sertraline is an officially documented mild inhibitor of CYP2D6, potentially raising the systemic exposure of co-administered CYP2D6 substrates. Conversely, strong CYP3A4 inducers may reduce Sertraline plasma levels. Interactions with supplements and food are noted, as Grapefruit Juice can increase Sertraline concentration, and concomitant use with alcohol is not recommended. For patients with hepatic impairment, a lower dose is required, as this condition significantly increases Sertraline and metabolite exposure.

Mechanism of Action

Targeted Serotonin Reuptake Inhibition

This mechanism acts within the domain of monoamine signaling by selectively blocking the serotonin transporter (SERT) protein, located on the presynaptic neuronal membrane. This interaction prevents the reabsorption of serotonin (5-HT) from the synaptic cleft, resulting in an increased concentration of the neurotransmitter available to act on postsynaptic receptors. This initial effect on the SERT initiates the subsequent molecular sequence.

Neuroadaptive Pathway Modulation

The prolonged availability of serotonin initiates complex mechanistic cascades that engage regulatory feedback mechanisms within the central nervous system. Over time, the persistent increase in serotonin causes crucial receptors to desensitize and adjust their functional density. This slow, adaptive process leads to changes in the activity of targeted pathways and engages feedback mechanisms that modulate physiological activity driven by specific signaling patterns.

Dosage and Administration Information

Sertraline Hydrochloride is exclusively administered via the oral route in the form of tablets, capsules, or an oral concentrate. The medicine is taken once daily. Standard usage begins with an initial daily dose of 25 mg or 50 mg, depending on the specific condition being addressed. The dosage is typically adjusted in increments of 25 mg to 50 mg per day no more frequently than once every week, up to a maximum recommended dose of 200 mg per day for adults across all approved indications.

Tablets may be administered with or without food. However, the oral concentrate formulation requires specific preparation: it must be diluted immediately before use by mixing the measured dose with exactly four ounces (half a cup) of water, ginger ale, lemon-lime soda, lemonade, or orange juice. The 150 mg and 200 mg capsules are not intended for use in treatment initiation or titration.

Usage instructions include specific rules for certain patient populations. For patients with mild hepatic impairment, the recommended starting and maximum dose must be reduced by 50%. For children aged 6–12 receiving Sertraline for Obsessive-Compulsive Disorder (OCD), the starting dose is 25 mg per day. When discontinuing the medication, the dose must be gradually reduced over a period of at least one to two weeks. Intermittent dosing, confined to the luteal phase of the menstrual cycle, is an official option for Premenstrual Dysphoric Disorder (PMDD).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zoloft (Sertraline)

Evidence for Major Depressive Disorder (MDD) and Prevention

Sertraline was studied for adults with Major Depressive Disorder. Researchers explored how symptoms change over time using multiple short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies typically monitored patients for periods of six to eight weeks, focusing on the measurement of changes in the overall severity of depressive symptoms. The studies also tracked global measures of the patients' condition and outcomes reflecting daily functioning.

To understand stability, researchers conducted long-term RCTs that specifically monitored patients for periods extending up to 20 months. These longer studies examined recurrence and relapse patterns in populations eligible for maintenance research.

Evidence for Obsessive-Compulsive Disorder (OCD)

Controlled trials for Obsessive-Compulsive Disorder (OCD) included both adults and pediatric patients (children and adolescents aged 6 to 17). These studies were used in research exploring how symptoms change over time, using a specialized scale (Y-BOCS) to measure the intensity of intrusive thoughts and compulsive behaviors. Extended studies explored long-term symptom maintenance, with observation periods extending up to 52 weeks.

Documented Research Gaps and Uncertainties

Documented scientific literature highlights several areas where research is ongoing or evidence quality varies across studies.

  • Long-term effects are not fully established for certain specific populations, especially regarding developmental outcomes in children and adolescents with OCD beyond the duration of the initial trials.
  • Data for certain groups remain insufficient, such as patients with severe impairment of kidney function or those with specific comorbidities like tic disorders.
  • Subgroup findings are uncertain in some areas, as some meta-analyses or regulatory reviews noted statistical heterogeneity (variability) in results when looking at specific populations (e.g., gender or trauma type in PTSD).

Key Studies & References

  1. Efficacy of Sertraline in Children and Adolescents with Obsessive-Compulsive Disorder (RCT)
  2. NICE Guideline [CG31]: Obsessive-compulsive disorder and body dysmorphic disorder: treatment

Frequently Asked Questions (FAQ)

Common questions about Zoloft (FAQ)

Q: Can Zoloft cause weight gain, and if so, how common is it?

A: Weight gain has been reported as an adverse reaction in official product documents, although it is not classified as one of the most common side effects. The official information more commonly lists decreased appetite as a reaction.


Q: Can Zoloft affect sleep patterns or cause insomnia?

A: Official product information states that insomnia (difficulty sleeping) is classified as a very common adverse reaction. Other effects documented in regulatory sources that can affect rest and energy include fatigue and drowsiness (somnolence).


Q: What is the process for safely stopping Zoloft?

A: According to official prescribing information, when discontinuing the medication, the dose must be gradually reduced over a period of at least one to two weeks. This gradual reduction is intended to minimize the potential for a discontinuation syndrome.


Q: Do people typically experience 'brain zaps' when stopping Zoloft?

A: The sudden cessation of treatment may lead to a discontinuation syndrome. Official documents describe that this syndrome may include sensory effects such as dizziness and electric shock-like sensations.


Q: Are there any documented long-term effects of taking Zoloft for many years?

A: Official long-term studies have examined recurrence and relapse patterns in adults for periods up to 20 months. Additionally, regulatory research tracks long-term safety points, such as developmental outcomes in pediatric patients.


Q: Can Zoloft change your appetite?

A: Yes, official product information indicates that Zoloft can change appetite. Decreased appetite is classified as a common adverse reaction.


Q: Do older adults use Zoloft differently than younger adults?

A: Regulatory guidance advises caution and closer monitoring due to potential differences in drug clearance in the elderly population. A mandated dose reduction is required for patients who also have mild hepatic impairment (reduced liver function).


Q: What happens if you miss a dose of Zoloft?

A: Guidance from official product information states that if a dose is missed, it can be taken as soon as remembered, unless it is near the time for the next dose. The guidance advises against taking a double dose to compensate for a missed one.


Q: How long does it usually take to feel the first effects of Zoloft?

A: While steady-state drug levels are typically achieved after approximately one week, more significant changes in mood are observed over several weeks. Initial minor changes, such as improved sleep or energy, may be noted earlier.


Q: Is it normal to feel worse when you first start taking Zoloft?

A: Official information notes that during the initial weeks of therapy or following a dose change, there is a documented risk of emergent or worsened symptoms. These can include agitation or anxiety, and the potential for suicidal thoughts in young adults (age 24 and younger).


Q: Can Zoloft interact with common pain relievers like ibuprofen?

A: The use of sertraline with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen, may increase the documented risk of bleeding. This is detailed in the official drug interaction sections.


Q: What is the expected timeline for Zoloft's full therapeutic effect?

A: Full therapeutic effects are generally observed over a course of several weeks. Regulatory reviews of clinical trials for Major Depressive Disorder typically monitored changes in symptoms over periods of six to eight weeks.


Q: Does Zoloft affect your ability to drive or operate machinery?

A: Official patient information states that sertraline may cause drowsiness or dizziness. Individuals are cautioned to wait until they know how the medication affects them before driving or operating machinery.


Q: Can Zoloft cause high blood pressure?

A: Increased blood pressure (hypertension) is a documented adverse reaction in official product information. It is also noted as a potential symptom of the rare, serious condition known as Serotonin Syndrome.


Q: Can Zoloft cause changes in vision?

A: Abnormal vision is listed as a potential adverse reaction in official product information. Furthermore, regulatory warnings note the potential for angle-closure glaucoma, which is a serious eye condition.


Q: Is Zoloft a Schedule II controlled substance?

A: No, sertraline (Zoloft) is not designated as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar international drug schedules.


Q: Does Zoloft have a sedative effect?

A: Official product information lists both drowsiness (somnolence) and fatigue as potential adverse reactions, which can indicate a sedative effect.


Q: Why is Zoloft sometimes prescribed for Premenstrual Dysphoric Disorder (PMDD)?

A: Sertraline is an FDA-approved treatment for Premenstrual Dysphoric Disorder (PMDD). This approval is based on clinical trials that examined its use, including continuous and intermittent dosing strategies, to manage symptoms.


Q: What clinical trials have been done on Zoloft for OCD?

A: Controlled trials for Obsessive-Compulsive Disorder (OCD) included short-term, placebo-controlled studies in adults and pediatric patients (ages 6 to 17). Longer studies, lasting up to 52 weeks, were also conducted to examine symptom maintenance.


Q: Does the time of day you take Zoloft matter?

A: Sertraline is prescribed to be taken once daily. Official information states that the tablets may be administered with or without food, giving flexibility in daily scheduling.


Q: Why do doctors check for a history of mania before prescribing Zoloft?

A: The regulatory label includes a warning that treatment may activate mania or hypomania in susceptible patients. Close monitoring is necessary for individuals with underlying Bipolar Disorder to watch for this risk.


Q: Can Zoloft interact with herbal supplements like St. John's Wort?

A: Concomitant use with other serotonergic agents, including the herbal supplement St. John's Wort, is advised against due to a documented increased risk of Serotonin Syndrome.


Q: Can Zoloft be taken with antacids?

A: Antacids are not specifically listed among the substances or medicines documented to interact with sertraline in official regulatory information.


Q: Can Zoloft cause nightmares or vivid dreams?

A: Abnormal dreams and other sleep disturbances are documented as potential adverse reactions in official product information.


Q: What are the possible withdrawal symptoms when discontinuing Zoloft?

A: Abruptly stopping treatment may result in a discontinuation syndrome. Documented symptoms can include dizziness, sensory disturbances, sleep disturbances, agitation, anxiety, headache, and nausea.


Q: What happens if you accidentally take two doses of Zoloft?

A: Official guidance advises against taking two doses at once. Documented symptoms of overdose include agitation, somnolence, and confusion. For concerns regarding an overdose, official guidance directs patients to contact emergency services or a poison control center.


Q: Are there specific conditions where Zoloft is considered inappropriate?

A: The regulatory label lists absolute contraindications, which are conditions or substances that strictly prohibit use, such as co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Pimozide.

How should Zoloft be stored and disposed of?

How to Store and Dispose of Zoloft (Sertraline)

Official regulatory guidelines strictly define how Zoloft must be stored to maintain its effectiveness and how it must be disposed of to ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect from excess heat, freezing, and moisture. Do not store in the bathroom.
Packaging Keep the medication in its original container and closed tightly.
Child Safety Must be kept out of the reach and sight of children.

Disposal Requirements

Do not use Zoloft past the expiration date. The preferred method for disposing of unused or expired Zoloft is through a drug take-back program or authorized collection site. To protect the environment, the medicine should generally not be disposed of by flushing down a toilet or pouring down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zoloft found in:

A-Z Index: